Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
最新データ
$3.72
−$0.05 · -1.33%
日中の時刻はETです。市場データは遅延する場合があります。
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
53
適正価値
センチメント
69
強気
リスク
48
やや高いリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 977.3万 USD | 833.3万 USD | 1545.1万 USD | 250.2万 USD | — |
| 売上原価 | — | — | — | 248.7万 USD | — |
| 粗利益 | 977.3万 USD | 833.3万 USD | 1545.1万 USD | 1.5万 USD | — |
| 研究開発 | 8640.3万 USD | 6600.1万 USD | 5677.8万 USD | 9116.9万 USD | 1.32億 USD |
| 販売・一般管理 | 3386.8万 USD | 2895.3万 USD | 3004.7万 USD | 3487.3万 USD | 4132.4万 USD |
| 営業費用 | 1.2億 USD | 9979.2万 USD | 8789万 USD | 1.26億 USD | 1.73億 USD |
| 受取利息 | 922.4万 USD | 694万 USD | 357.2万 USD | 24.9万 USD | 17.2万 USD |
| 支払利息 | 6.3万 USD | 10.2万 USD | 499.8万 USD | 379.8万 USD | 142.8万 USD |
| 減価償却費と償却費 | 114.5万 USD | 124.5万 USD | 137.1万 USD | 117.2万 USD | 49.2万 USD |
| 営業利益 | −1.1億 USD | −9145.9万 USD | −7243.9万 USD | −1.26億 USD | −1.73億 USD |
| 純利益 | −1.09億 USD | −8929.8万 USD | −1.12億 USD | −1.66億 USD | −1.75億 USD |
会社概要が更新されました 2026年11月22日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2990.67万0.00%6893億 USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM2655.08万0.04%715.37億 USD0.19%$256.61-2.88%
State Street SPDR S&P Biotech ETFXBI1985.78万0.21%96.36億 USD0.35%$140.18-2.73%
Vanguard Extended Market ETFVXF1274.66万0.01%302億 USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO945.27万0.07%127.32億 USD0.24%$320.43-3.57%
iShares Biotechnology ETFIBB762.19万0.07%105.27億 USD0.44%$199.54-2.05%
Vanguard Russell 2000 ETFVTWO647.96万0.04%168億 USD0.06%$103.76-2.76%
Schwab U.S. Small-Cap ETFSCHA535.68万0.03%204.47億 USD0.03%$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
State Street SPDR S&P Biotech ETFXBI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。